ENTITY
Daiichi Sankyo

Daiichi Sankyo (4568 JP)

222
Analysis
Health Care • Japan
Daiichi Sankyo Co, Ltd is a holding company established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
more
•13 Dec 2016 11:44

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

•03 Dec 2016 18:43

American Society of Hematology (ASH) -Annual Conference (2016) Preview

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...

•23 Nov 2016 12:14

Why Hold Japan, Part II: Comparative Valuation Among G7 Economies

"Why Hold Japan?" is a question that recurs among foreign investors, now the greatest cohort of investors in Japanese stocks.  The question tends...

Logo
331 Views
Share
•11 Nov 2016 12:05

President Trump and Healthcare (And Pharma) Sector: What's Next?

Now that the initial shock period is over, we return to finding out how President Trump could affect the U.S. (and with it the global) healthcare...

•01 Nov 2016 13:06

Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update

 Acadia Pharmaceuticals Inc (ACAD US), our portfolio company announced the initiation of a phase 2 study of Nuplazid in Alzheimer's related...

x